Roivant Strikes $5.5 Million China Deal with ArQule for Cancer Drug

Roivant Sciences, a Swiss-US in-licensing company, announced a collaboration with ArQule to develop derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China. Roivant will make an upfront payment to ArQule of $3 million and pay $2.5 million in development milestones within the first year. ArQule will be eligible for regulatory and commercial milestones plus royalties on China sales of derazantinib in Greater China. Roivant had not previously been involved with China . More details.... Stock Symbol: (NSDQ: ARQL) Share this with colleagues: // //